WO2009085272A3 - Improved medical devices - Google Patents

Improved medical devices Download PDF

Info

Publication number
WO2009085272A3
WO2009085272A3 PCT/US2008/014023 US2008014023W WO2009085272A3 WO 2009085272 A3 WO2009085272 A3 WO 2009085272A3 US 2008014023 W US2008014023 W US 2008014023W WO 2009085272 A3 WO2009085272 A3 WO 2009085272A3
Authority
WO
WIPO (PCT)
Prior art keywords
medical devices
improved medical
improved
introduction
subject
Prior art date
Application number
PCT/US2008/014023
Other languages
French (fr)
Other versions
WO2009085272A9 (en
WO2009085272A2 (en
Inventor
Bradford J. Duft
Colin R. Green
David L. Becker
Original Assignee
Coda Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coda Therapeutics, Inc. filed Critical Coda Therapeutics, Inc.
Priority to EP08867503A priority Critical patent/EP2234656A2/en
Priority to US12/809,941 priority patent/US9035037B2/en
Priority to CA2710386A priority patent/CA2710386A1/en
Priority to JP2010539515A priority patent/JP2011507599A/en
Priority to AU2008343843A priority patent/AU2008343843A1/en
Publication of WO2009085272A2 publication Critical patent/WO2009085272A2/en
Publication of WO2009085272A9 publication Critical patent/WO2009085272A9/en
Publication of WO2009085272A3 publication Critical patent/WO2009085272A3/en
Priority to US14/715,282 priority patent/US9561311B2/en
Priority to US15/424,758 priority patent/US10251929B2/en
Priority to US16/378,402 priority patent/US20190290719A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A61L2300/608—Coatings having two or more layers

Abstract

Medical devices comprising an anti-connexin agent suitable for introduction into a subject.
PCT/US2008/014023 2007-12-21 2008-12-22 Improved medical devices WO2009085272A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP08867503A EP2234656A2 (en) 2007-12-21 2008-12-22 Improved medical devices
US12/809,941 US9035037B2 (en) 2007-12-21 2008-12-22 Medical devices
CA2710386A CA2710386A1 (en) 2007-12-21 2008-12-22 Improved medical devices
JP2010539515A JP2011507599A (en) 2007-12-21 2008-12-22 Improved medical device
AU2008343843A AU2008343843A1 (en) 2007-12-21 2008-12-22 Improved medical devices
US14/715,282 US9561311B2 (en) 2007-12-21 2015-05-18 Medical devices
US15/424,758 US10251929B2 (en) 2007-12-21 2017-02-03 Medical devices
US16/378,402 US20190290719A1 (en) 2007-12-21 2019-04-08 Medical devices

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US873807P 2007-12-21 2007-12-21
US61/008,738 2007-12-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/809,941 A-371-Of-International US9035037B2 (en) 2007-12-21 2008-12-22 Medical devices
US14/715,282 Division US9561311B2 (en) 2007-12-21 2015-05-18 Medical devices

Publications (3)

Publication Number Publication Date
WO2009085272A2 WO2009085272A2 (en) 2009-07-09
WO2009085272A9 WO2009085272A9 (en) 2010-06-10
WO2009085272A3 true WO2009085272A3 (en) 2010-07-29

Family

ID=40466841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/014023 WO2009085272A2 (en) 2007-12-21 2008-12-22 Improved medical devices

Country Status (6)

Country Link
US (4) US9035037B2 (en)
EP (1) EP2234656A2 (en)
JP (4) JP2011507599A (en)
AU (1) AU2008343843A1 (en)
CA (1) CA2710386A1 (en)
WO (1) WO2009085272A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047335T2 (en) 2005-02-03 2020-04-28 Coda Therapeutics Ltd Anti-connexin 43 compounds for treating chronic wounds
AU2008343841A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of inhibitors of connexin43 for treatment of fibrotic conditions
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
KR102038948B1 (en) 2012-03-01 2019-11-26 퍼스트스트링 리서치 인코포레이티드 Topical Gels Containing Alpha Connexin C-Terminal (ACT) Peptides
CN114010788A (en) 2014-08-22 2022-02-08 奥克兰联合服务有限公司 Channel modulators
CN105498074B (en) * 2015-12-25 2017-08-08 李雷 vascular wall repair system
WO2017190152A1 (en) * 2016-04-29 2017-11-02 Ocunexus Therapeutics, Inc. Sustained release drug delivery devices
RU2636418C1 (en) * 2017-03-16 2017-11-23 Дмитрий Викторович Давыдов Method for exophtalm correction and implant to increase orbit volume near formed bone defect in case of exophtalm correction
JP2020517714A (en) 2017-04-28 2020-06-18 オークランド ユニサービシズ リミテッド Treatment method and new construct
WO2019152917A1 (en) 2018-02-02 2019-08-08 Galen Therapeutics Llc Apparatus and method for protecting neurons and reducing inflammation and scarring
WO2023219655A1 (en) * 2022-05-13 2023-11-16 University Of Utah Research Foundation Gja1-20k to limited cardiac arrhythmias

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044409A1 (en) * 1999-01-27 2000-08-03 University College London Formulations comprising antisense nucleotides to connexins
WO2006134494A2 (en) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and therapeutic uses thereof
WO2009075882A2 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861757A (en) * 1986-11-14 1989-08-29 Institute Of Molecular Biology Wound healing and bone regeneration using PDGF and IGF-I
US4916193A (en) * 1987-12-17 1990-04-10 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5092877A (en) * 1988-09-01 1992-03-03 Corvita Corporation Radially expandable endoprosthesis
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US4994071A (en) * 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5163952A (en) * 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
US5599352A (en) * 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5857998A (en) * 1994-06-30 1999-01-12 Boston Scientific Corporation Stent and therapeutic delivery system
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6566339B1 (en) * 1995-08-04 2003-05-20 Renovo Limited Pharmaceutical composition
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
JPH11513405A (en) * 1995-10-11 1999-11-16 カイロン コーポレイション Formulations of PDGF, KGF, IGF, and IGFBP for wound healing
AU734465B2 (en) * 1996-07-22 2001-06-14 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
GB9702943D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Wound healing
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6855505B2 (en) * 1998-06-26 2005-02-15 Renovo Limited Method for quantifying TGF-β
ATE292473T1 (en) 1998-07-30 2005-04-15 Us Gov Health & Human Serv THYMOSIN BETA 4 STIMULATES WOUND HEALING
DE19902481A1 (en) * 1999-01-22 2000-07-27 Signus Medizintechnik Gmbh Vertebra replacement for replacing diseased or damaged vertebra in surgical procedures, has anchoring side and gripping screw
GB9903598D0 (en) * 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
US6251136B1 (en) * 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US7250397B2 (en) * 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
JP2005509621A (en) 2001-10-17 2005-04-14 ユニバーシティ オブ ウェールズ カレッジ オブ メディスン Gap junction and EDHF
CN1638790A (en) * 2002-01-29 2005-07-13 Wyeth公司 Compositions and methods for modulating connexin hemichannels
US6702850B1 (en) * 2002-09-30 2004-03-09 Mediplex Corporation Korea Multi-coated drug-eluting stent for antithrombosis and antirestenosis
CA3059497A1 (en) * 2003-12-03 2005-06-16 Ocunexus Therapeutics, Inc. Antisense compounds targeted to connexins and methods of use thereof
HUE038099T2 (en) 2004-12-21 2018-09-28 Musc Found For Res Dev Compositions and methods for promoting wound healing and tissue regeneration
US7829527B2 (en) * 2005-02-02 2010-11-09 University Of Vermont And State Agricultural College Emergence of a R-type Ca2+ channel (Cav 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044409A1 (en) * 1999-01-27 2000-08-03 University College London Formulations comprising antisense nucleotides to connexins
WO2006134494A2 (en) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and therapeutic uses thereof
WO2009075882A2 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments

Also Published As

Publication number Publication date
JP2011507599A (en) 2011-03-10
AU2008343843A1 (en) 2009-07-09
WO2009085272A9 (en) 2010-06-10
US9035037B2 (en) 2015-05-19
US20110166653A1 (en) 2011-07-07
US20150297804A1 (en) 2015-10-22
JP2015006440A (en) 2015-01-15
US20190290719A1 (en) 2019-09-26
US9561311B2 (en) 2017-02-07
JP2018198954A (en) 2018-12-20
EP2234656A2 (en) 2010-10-06
WO2009085272A2 (en) 2009-07-09
US10251929B2 (en) 2019-04-09
JP2017064431A (en) 2017-04-06
CA2710386A1 (en) 2009-07-09
US20170189469A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
WO2009085272A3 (en) Improved medical devices
JP1322466S (en) An earphone
EP2351509A4 (en) Medical device
EP2244760B8 (en) An implantable drainage device
EP2244667B8 (en) An implantable fluid movement device
IL197936A0 (en) Implantable device
GB0620359D0 (en) Medical devices
GB0618612D0 (en) Medical device
GB0715798D0 (en) Lancing devices
GB2436526B (en) Syringe
GB2451840B (en) Lancing devices
EP2008335A4 (en) Improved electrochemical device
EP2010280A4 (en) Medical device
EP2327937A4 (en) Diagnostic aid device
EP2315709A4 (en) Sharps handling devices
EP2085016A4 (en) Medical device
GB0622970D0 (en) Medical device
GB2456401A9 (en) Ion handling devices.
ZA201103535B (en) An implantable medical device
EP2015810A4 (en) Improved syringe
GB0617134D0 (en) Medical devices
EP2344106B8 (en) Heart help device
GB0715800D0 (en) Lancing devices
GB2438824B (en) Cleaner for medical or veterinary devices, for example auriscopes
GB0617083D0 (en) Medical device

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08867503

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010539515

Country of ref document: JP

Ref document number: 2710386

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008867503

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008343843

Country of ref document: AU

Ref document number: 5279/DELNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008343843

Country of ref document: AU

Date of ref document: 20081222

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12809941

Country of ref document: US